ATE258063T1 - Selektive mmp inhibitoren mit verringerten nebenwirkungen - Google Patents

Selektive mmp inhibitoren mit verringerten nebenwirkungen

Info

Publication number
ATE258063T1
ATE258063T1 AT98908225T AT98908225T ATE258063T1 AT E258063 T1 ATE258063 T1 AT E258063T1 AT 98908225 T AT98908225 T AT 98908225T AT 98908225 T AT98908225 T AT 98908225T AT E258063 T1 ATE258063 T1 AT E258063T1
Authority
AT
Austria
Prior art keywords
reduced side
side effects
mmp inhibitors
mmp
selective mmp
Prior art date
Application number
AT98908225T
Other languages
English (en)
Inventor
John Bird
John Gary Montana
Ruth Elizabeth Wills
Andrew Douglas Baxter
David Alan Owen
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704350.9A external-priority patent/GB9704350D0/en
Priority claimed from GBGB9802622.2A external-priority patent/GB9802622D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE258063T1 publication Critical patent/ATE258063T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98908225T 1997-03-03 1998-03-03 Selektive mmp inhibitoren mit verringerten nebenwirkungen ATE258063T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9704350.9A GB9704350D0 (en) 1997-03-03 1997-03-03 Compounds and their therapeutic use
GBGB9802622.2A GB9802622D0 (en) 1998-02-06 1998-02-06 Compounds and their therapeutic use
PCT/GB1998/000659 WO1998039024A1 (en) 1997-03-03 1998-03-03 Selective mmp inhibitors having reduced side-effects

Publications (1)

Publication Number Publication Date
ATE258063T1 true ATE258063T1 (de) 2004-02-15

Family

ID=26311105

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98908225T ATE258063T1 (de) 1997-03-03 1998-03-03 Selektive mmp inhibitoren mit verringerten nebenwirkungen

Country Status (9)

Country Link
US (1) US6818622B2 (de)
EP (1) EP0981366B1 (de)
JP (1) JP2001513813A (de)
AT (1) ATE258063T1 (de)
AU (1) AU741903C (de)
CA (1) CA2280134A1 (de)
DE (1) DE69821228T2 (de)
ES (1) ES2212270T3 (de)
WO (1) WO1998039024A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347911A1 (en) * 1998-10-23 2000-05-04 Darwin Discovery Limited Single morphic forms of known peptide metalloproteinase inhibitors
WO2001026671A1 (en) * 1999-10-12 2001-04-19 Smithkline Beecham Corporation Methods of treatment using dual matrix-metalloproteinase-2 and matrix metalloproteinase-9 inhibitors
CN101456860B (zh) * 2007-12-10 2011-02-16 中国科学院上海药物研究所 4-[9-(6-氨基嘌呤基)]-2(s)-羟基丁酸甲酯的制备方法
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
JPH08500124A (ja) * 1993-04-27 1996-01-09 セルテック セラピューティックス リミテッド メタロプロテイナーゼインヒビターとしてのペプチジル誘導体
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
CZ288436B6 (en) * 1994-10-05 2001-06-13 Darwin Discovery Ltd Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
AU706064B2 (en) * 1995-05-10 1999-06-10 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and TNF liberation, and their therapeutic use
WO1997012902A1 (en) * 1995-10-05 1997-04-10 Darwin Discovery Limited Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use

Also Published As

Publication number Publication date
JP2001513813A (ja) 2001-09-04
US6818622B2 (en) 2004-11-16
EP0981366B1 (de) 2004-01-21
AU6630698A (en) 1998-09-22
CA2280134A1 (en) 1998-09-11
ES2212270T3 (es) 2004-07-16
US20020035065A1 (en) 2002-03-21
DE69821228D1 (de) 2004-02-26
WO1998039024A1 (en) 1998-09-11
AU741903B2 (en) 2001-12-13
EP0981366A1 (de) 2000-03-01
DE69821228T2 (de) 2004-10-21
AU741903C (en) 2002-09-05

Similar Documents

Publication Publication Date Title
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
MY129409A (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
TR28718A (tr) Dinamik takilan tipte cocuk bezi.
DE69925133D1 (de) Pyrrolobenzodiazepine
ATE282600T1 (de) Salpetersäuresalze von antihypertensiven arzneimitteln
DE69621021D1 (de) Inhibitoren der plättchenaggregation
YU53899A (sh) Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
KR970005391A (ko) 고활성 이중 금속 시아나이드 착물 촉매
AR015379A1 (es) Ascorbil-fosforil-colesterol
DE69115280D1 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
DE69716934D1 (de) 1,3-diheterozyklische metalloprotease inhibitoren
TR199802106A3 (tr) Sübstitüe edilmis izokinolin-3-karbon asidi amidleri.
DK1032414T3 (da) Kombination af inhibitor for angiotensinomdannende enzym med et diuretikum til behandling af forstyrrelser i mikrokredsløbet
DE69838042D1 (de) Verwendung von Inhibitoren des Renin-Angiotensin Systems
DE59407238D1 (de) Aktiver schalldämpfer
DK0859784T3 (da) Thiosubstituerede peptider som inhibitorer af metalloproteinaser og TNF-frigivelse
TR199900505T2 (de)
BR9608594B1 (pt) misturas de benzimidazóis substituìdos para o combate de protozoários parasìticos.
EA199800367A1 (ru) Таблетка меченной изотопом мочевины
BR9809848A (pt) Composição
ZA978307B (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase.
IT1302243B1 (it) Sintesi dell'1,1,1,3,3-pentafluoropropano.
ES2186807T3 (es) Inhibidores de trombina.
BG100248A (bg) Инхибитори на скваленсинтетаза
ID24677A (id) Kombinasi senyawa aktif fungisidal

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties